Company Filing History:
3 out of 832,880 Years Active: 2006-2013
Title: Elham Khatamzas: Innovator in Immunology
Introduction
Elham Khatamzas is a prominent inventor based in Berlin, Germany. She has made significant contributions to the field of immunology, particularly in the development of peptides for vaccination against human cytomegalovirus (CMV). With a total of 3 patents, her work is paving the way for advancements in vaccine technology.
Latest Patents
One of her latest patents focuses on "Peptides for vaccination against human CMV." This invention relates to peptides or pretide derivatives of the 65kD lower matrix phosphoprotein of human cytomegalovirus. The disclosed peptides are useful for determining whether subjects have been exposed to human cytomegalovirus. Additionally, methods for using these peptides or derivatives to determine the peptide-induced production of interferon-γ and/or TNF-α in CD8 T cells isolated from subjects are also included.
Another significant patent is titled "Method for antigen-specific stimulation of T lymphocytes with synthetic peptide libraries." This invention describes a method for the antigen-specific stimulation of T-lymphocytes using a synthetic peptide library. The process involves preparing a plurality of peptides, each comprising a fragment of the total amino acid sequence of the antigen, and incubating a suspension of CD8+ T lymphocytes, CD4+ T lymphocytes, or a mixture of both with the peptide library.
Career Highlights
Elham Khatamzas has worked with various organizations throughout her career. Notably, she has collaborated with professionals in her field, enhancing her research and innovation capabilities.
Collaborations
Some of her notable coworkers include Florian Kern and Hans-Dieter Volk. Their collaboration has contributed to the advancement of her research and the successful development of her patents.
Conclusion
Elham Khatamzas is a trailblazer in the field of immunology, with her innovative patents addressing critical health challenges. Her work continues to inspire advancements in vaccine development and immunotherapy.